(2020). Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions. Am Health Drug Benefits.
Styl Chicago"Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC With RET Fusions." Am Health Drug Benefits 2020.
Citace podle MLA"Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC With RET Fusions." Am Health Drug Benefits 2020.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..